Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL).
暂无分享,去创建一个
C. Wilson | H. Kantarjian | G. Garcia-Manero | J. Cortes | T. Kadia | F. Ravandi | E. Jabbour | S. O'brien | A. Advani | S. Faderl | D. Thomas | M. Kwari | S. York | R. Tarnai